Singular Genomics Systems (NASDAQ:OMIC) Trading Up 3.2% – What’s Next?

Singular Genomics Systems, Inc. (NASDAQ:OMIC)’s stock price traded up 3.2% during mid-day trading on Friday . The stock traded as high as $20.40 and last traded at $20.02. 4,808 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 33,283 shares. The stock had previously closed at $19.40.

Singular Genomics Systems Stock Up 3.2 %

The company has a current ratio of 7.37, a quick ratio of 6.67 and a debt-to-equity ratio of 0.04. The business’s 50-day simple moving average is $18.19 and its 200-day simple moving average is $12.35. The company has a market capitalization of $50.25 million, a PE ratio of -0.57 and a beta of 1.82.

Singular Genomics Systems (NASDAQ:OMIC) last posted its earnings results on Tuesday, November 12th. The company reported ($6.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.05) by $1.33. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $0.74 million. Singular Genomics Systems had a negative net margin of 3,237.89% and a negative return on equity of 57.87%.

Institutional Investors Weigh In On Singular Genomics Systems

A hedge fund recently raised its stake in Singular Genomics Systems stock. Geode Capital Management LLC lifted its holdings in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 7.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,962 shares of the company’s stock after purchasing an additional 1,193 shares during the period. Geode Capital Management LLC owned about 0.72% of Singular Genomics Systems worth $282,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 65.80% of the company’s stock.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.